Industry context
Moderna Inc [MRNA]
Última actualización 25 Jun 2026 @ 16:00 (Exchange is closed)
Último: $59.75
-1.11%
3.27 (↓)
GaG Algo Score™
v1.0
Corto
3.27 (↓)
Medio
4.71 (↓)
Largo
4.44 (↓)
COMPRAR
60.00%
rentabilidad 4.94%
VENDER
63.27%
rentabilidad -9.02%
Línea
Datos pivot
Estadísticas pivot
| Métrica | Promedio | Mediana | Desv. est. |
|---|---|---|---|
| Ganancia % | 16.41% | 16.41% | 4.78% |
| Pérdida % | -13.44% | -13.44% | 3.66% |
| Duración | 10.0d | 7d | 10.2d |
| Pivots encontrados | 5 |
| Tramos ganancia/pérdida | 4 (2 Ganancia / 2 Pérdida) |
| Último pivot | Bottom @ $45.99 el 2026-06-10 |
| Cambio desde el último pivot | $13.76 (29.92%) |
Predicción del próximo pivot Último: $59.75
| Próximo tipo previsto | Top |
| Precio previsto (prom.) | $53.54 |
| Precio previsto (mediana) | $53.54 |
| Rango de precio previsto (~68%) | $51.34 - $55.74 |
| Cambio al objetivo promedio | $-6.21 (-10.39%) |
| Fecha prevista (prom.) | 2026-06-20 |
| Rango de fechas previsto (~68%) | 2026-06-09 - 2026-06-30 |
| Base | Based on 2 historical gains (Avg: 16.41%, Median: 16.41%, StdDev: 4.78%) and duration (Avg: 10.0 days, StdDev: 10.2 days) |
| Nota | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Moderna Inc lost modestly, down -1.11%.
Moderna Inc (MRNA) stock price declined on Thursday after the stock fell $-0.670 (-1.11%) from the previous session on below-average volume. The stock fell slightly more than the NASDAQ which was down -0.46%. With 6.16M shares traded, volume yesterday reached $368.25M. This was 5.54M shares less than the prior day. Compared to the 10-day average of 9.83M shares, volume was less than the average.
Moderna Inc signals
There is no conclusive signals given from RSI. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (40%), medium- (40%), and long-term (40%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Moderna Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $60.40. approximately $0.650 (1.09%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $61.8. On a fall back there will be support at $28.1 The dis das resistance s128.1 -
Moderna Inc Evaluation
- Corto puntuación: 3.27
- Medio puntuación: 4.71
- Largo puntuación: 4.44
Ownership flow
GetAGraph InsiderPower
Transactions
387
Buy power
157.99M
Sell power
40.39M
Reliability
100/100
Buy / sell
3.91
Hist. corr.
-0.83
Latest signal
Sell 2026-06-22
Officer 197
Director 98
Executive 92
2026-06-15
Hoge Stephen Executive
Buy 37 226
2026-06-15
Hoge Stephen Executive
Buy 16 110
2026-06-15
Hoge Stephen Executive
Sell 53 336
2026-06-05
Klinger Shannon Thyme Officer
Buy 11 798
2026-06-05
Klinger Shannon Thyme Officer
Other 5 705
2026-06-05
Mock James M Officer
Buy 11 798
Relationship map
Correlation snapshot
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.88% <strong>$60.27</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
14.80%
Of outstanding shares
Short float
15.87%
Of tradable float
Days to cover
12.27
Short interest divided by average volume
Squeeze probability
79.60%
-0.46% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
9
EPS misses
1
Avg. surprise
41.75%
Moderna Inc Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Beat
Q2/2023
Beat
Q3/2023
Beat
Q4/2023
Beat
Q1/2024
Beat
Q2/2024
Beat
Q3/2024
Beat
Q4/2024
Beat
Q1/2025
Waiting
Q2/2025
Waiting
Q3/2025
Moderna Inc Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Q3/2025 | - | - | Waiting | - | - | Waiting |
| 2025-08-07 | Q2/2025 | $-3.00 | - | Waiting | - | - | Waiting |
| 2025-05-01 | Q1/2025 | $-2.92 | $-2.52 | Beat 13.70% | 116.75M | 107.00M | Miss -8.35% |
| 2025-02-14 | Q4/2024 | $-2.68 | $-2.50 | Beat 6.72% | 942.82M | 956.00M | Beat 1.40% |
| 2024-11-07 | Q3/2024 | $-1.910 | $0.0300 | Beat 101.57% | 1.25B | 1.86B | Beat 48.39% |
| 2024-08-01 | Q2/2024 | $-3.35 | $-3.33 | Beat 0.60% | 128.41M | 241.00M | Beat 87.68% |
| 2024-05-02 | Q1/2024 | $-3.56 | $-3.07 | Beat 13.76% | 93.26M | 167.00M | Beat 79.07% |
| 2024-02-22 | Q4/2023 | $-0.970 | $0.550 | Beat 156.70% | 2.51B | 2.81B | Beat 12.02% |
| 2023-11-02 | Q3/2023 | $-2.01 | $-1.390 | Beat 30.85% | 1.32B | 1.83B | Beat 38.27% |
| 2023-08-03 | Q2/2023 | $-3.84 | $-3.62 | Beat 5.73% | 319.64M | 344.00M | Beat 7.62% |
| 2023-05-04 | Q1/2023 | $-1.770 | $0.190 | Beat 110.73% | 1.18B | 1.84B | Beat 56.01% |
| 2023-02-23 | Q4/2022 | $4.68 | $3.61 | Miss -22.86% | 5.02B | 5.08B | Beat 1.33% |
Analyst view
Analyst targets
Consensus
$40.29
Median
$38.00
Low
$33.00
High
$49.00
News flow
Latest company news
Market coverage
seekingalpha.com Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript Jun 25, 2026 accessnewswire.com Moderna Science Day Highlights Expanding Potential of mRNA Platform Jun 25, 2026 zacks.com Moderna (MRNA) Rises As Market Takes a Dip: Key Facts Jun 23, 2026 schaeffersresearch.com Major Indexes Continue Lower as Chip Selloff Drags Nasdaq Jun 23, 2026Company releases
Company context
Company profile
Bolsa:
NASDAQ
Sector:
Healthcare
Industria:
Biotechnology
Currency
USD
Moderna Inc a biotechnology firm is dedicated to the discovery development and commercialization of messenger RNA mRNA based therapies and preventive medicines Its extensive research and development efforts target a broad spectrum of medical needs including infectious diseases cancer immunology rare conditions cardiovascular ailments and autoimmune disorders with operations spanning the United States Europe and other global markets The companys diverse product pipeline encompasses various vaccine candidates those for respiratory illnesses like COVID19 influenza and respiratory syncytial virus RSV latent viral infections such as cytomegalovirus CMV EpsteinBarr virus EBV human immunodeficiency virus HIV herpes simplex virus HSV and varicellazoster virus VZV and public health threats like Zika and Nipah Additionally Moderna is advancing systemic secreted and cell surfacetargeted therapeutics an array of cancer vaccines including personalized KRAS and checkpoint varieties intratumoral immunooncology products localized regenerative treatments systemic intracellular medicines and inhaled pulmonary solutions Moderna maintains strategic alliances with several prominent entities including AstraZeneca PLC Merck Co Inc Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Europe Limited Carisma Therapeutics Inc Metagenomi Inc the Defense Advanced Research Projects Agency DARPA the Biomedical Advanced Research and Development Authority BARDA the Institute for Life Changing Medicines and The Bill Melinda Gates Foundation It also holds a collaboration and license agreement with Chiesi Farmaceutici SPA Founded in 2010 as Moderna Therapeutics Inc the company officially became Moderna Inc in August 2018 Its corporate headquarters are located in Cambridge Massachusetts
Navigation